Raloxifene and ICI182,780 increase estrogen receptor-α association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12

Molecular Endocrinology

Volumn 21, Issue 4, 2007, Pages 797-816

  Lupien, Mathieu ^a   Jeyakumar, M ^b   Hébert, Elise ^c   Hilmi, Khalid ^c,d   Cotnoir White, David ^d   Loch, Caroline ^e   Auger, Anick ^c   Dayan, Guila ^c   Pinard, Geneviève Anne ^c   Wurtz, Jean Marie ^e   Moras, Dino ^e   Katzenellenbogen, John ^b   Mader, Sylvie ^a,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^e INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIESTROGEN; BINDING PROTEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN HELIX 12 PROTEIN; FULVESTRANT; MUTANT PROTEIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ESTRADIOL; LEUCINE; TFF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CELL NUCLEUS; CELL STRAIN HEPG2; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HYDROPHOBICITY; LIGAND BINDING; MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR GENE; REPORTER GENE; SOLUBILITY; STEREOSPECIFICITY; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; AMINO ACID SEQUENCE; CELL CULTURE; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR GENETICS; PROTEIN MOTIF; PROTEIN SECONDARY STRUCTURE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO ACIDS; CELL NUCLEUS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; HUMANS; LEUCINE; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN STRUCTURE, SECONDARY; RALOXIFENE; SOLUBILITY; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 34247898925     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2006-0074     Document Type: Article

References (87)

1. Couse JF, Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us. Endocr Rev 20:358-417
2. McEwen BS, Alves SE 1999 Estrogen actions in the central nervous system. Endocr Rev 20:279-307
3. Jordan VC 2001 Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. J Natl Canc Inst 93:2-4
4. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565
5. Green S, Chambon P 1988 Nuclear receptors enhance our understanding of transcription regulation. Trends Genet 4:309-314
6. Beato M, Herrlich P, Schutz G 1995 Steroid hormone receptors: many actors in search of a plot. Cell 83:851-857
7. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans, RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839
8. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ 2001 Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-1870
9. Robinson-Rechavi M, Escriva Garcia H, Laudet V 2003 The nuclear receptor superfamily. J Cell Sci 116:585-586
10. Pratt WB, Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360
11. Ylikomi T, Wurtz JM, Syvala H, Passinen S, Pekki A, Haverinen M, Blauer M, Tuohimaa P, Gronemeyer H 1998 Reappraisal of the role of heat shock proteins as regulators of steroid receptor activity. Crit Rev Biochem Mol Biol 33:437-466
12. Burakov D, Crofts LA, Chang CP, Freedman LP 2002 Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. J Biol Chem 277:14359-14362
13. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852
14. Metivier R, Stark A, Flouriot G, Hubner MR, Brand H, Penot G, Manu D, Denger S, Reid G, Kos M, Russell RB, Kah O, Pakdel F, Gannon F 2002 A dynamic structural model for estrogen receptor-α activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol Cell 10:1019-1032
15. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695-707
16. Leo C, Chen JD 2000 The SRC family of nuclear receptor coactivators. Gene 245:1-11
17. Rosenfeld MG, Glass CK 2001 Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865-36868
18. Rachez C, Freedman LP 2001 Mediator complexes and transcription. Curr Opin Cell Biol 13:274-280
19. Dilworth FJ, Chambon P 2001 Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene 20:3047-3054
20. McDonnell DP, Norris JD 2002 Connections and regulation of the human estrogen receptor. Science 296:1642-1644
21. Belandia B, Parker MG 2003 Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell 114:277-280
22. Krust A, Green S, Argos P, Kumar V, Walter P, Bornert JM, Chambon P 1986 The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J 5:891-897
23. Mader S, Chambon P, White JH 1993 Defining a minimal estrogen receptor DNA binding domain. Nucleic Acids Res 21:1125-1132
24. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU 1986 An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46:1053-1061
25. Klinge CM 2001 Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905-2919
26. Sanchez R, Nguyen D, Rocha W, White JH, Mader S 2002 Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 24:244-254
27. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S 2004 Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18:1411-1427
28. Leid M, Kastner P, Chambon P 1992 Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 17:427-433
29. Gustafsson J-A 1999 Estrogen receptor β - a new dimension in estrogen mechanim of action. J Endocrinol 163:379-383
30. Dunn BK, Ford LG 2001 From adjuvant therapy to breast cancer prevention: bcpt and star. Breast J 7:144-147
31. O'Regan RM, Jordan VC 2001 Chemoprevention of breast cancer. Cancer Treat Res 106:137-154
32. Jordan VC 2003 Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205-213
33. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
34. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA 1997 Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94:14105-14110
35. Bowler J, Lilley TJ, Pittam JD, Wakeling AE 1989 Novel steroidal pure antiestrogens. Steroids 54:71-99
36. Wakeling AE, Dukes M, Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
37. Van de Velde P, Nique F, Bouchoux F, Bremaud J, Hameau MC, Lucas D, Moratille C, Viet S, Philibert D, Teutsch G 1994 RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J Steroid Biochem Mol Biol 48:187-196
38. Berry M, Metzger D, Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818
39. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30
40. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705
41. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
42. Keeton EK, Brown M 2005 Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19:1543-1554
43. Webb P, Nguyen P, Kushner PJ 2003 Differential SERM effects on corepressor binding dictate ERα activity in vivo. J Biol Chem 278:6912-6920
44. Dauvois S, Danielian PS, White R, Parker MG 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041
45. Devin-Leclerc J, Meng X, Delahaye F, Leclerc P, Baulieu EE, Catelli MG 1998 Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol Endocrinol 12:842-854
46. Borras M, Laios I, el Khissiin A, Seo HS, Lempereur F, Legros N, Leclercq G 1996 Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 57:203-213
47. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96:1858-1862
48. Wijayaratne AL, McDonnell DP 2001 The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276:35684-35692
49. Marsaud V, Gougelet A, Maillard S, Renoir JM 2003 Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor α (ERα), differentially affect ERα extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol 17:2013-2027
50. Dauvois S, White R, Parker MG 1993 The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388
51. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini MA 2001 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nat Cell Biol 3:15-23
52. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Merand Y, Belanger A, Labrie C, Labrie F 1997 Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res 57:3494-3497
53. Levenson AS, Jordan VC 1998 The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58:1872-1875
54. Barsalou A, Dayan G, Anghel SI, Alaoui-Jamali M, Van de Velde P, Mader S 2002 Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells. Mol Cell Endocrinol 190:65-73
55. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP 1999 Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140:5828-5840
56. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
57. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
58. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
59. Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li YL, Gustafsson JA, Carlquist M 2001 Structural insights into the mode of action of a pure antiestrogen. Structure (Camb) 9:145-153
60. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W 1995 Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92:4206-4210
61. Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS 1996 Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10:230-242
62. Norris JD, Fan D, Stallcup MR, McDonnell DP 1998 Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. J Biol Chem 273:6679-6688
63. Fan JD, Wagner BL, McDonnell DP 1996 Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol Endocrinol 10:1605-1616
64. Metivier R, Penot G, Flouriot G, Pakdel F 2001 Synergism between ERα transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 α-helical core and for a direct interaction between the N- and C-terminal domains. Mol Endocrinol 15:1953-1970
65. Castro-Rivera E, Safe S 2003 17β-Estradiol- and 4-hydroxytamoxifen- induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context. J Steroid Biochem Mol Biol 84:23-31
66. Gibson MK, Nemmers LA, Beckman Jr WC, Davis VL, Curtis SW, Korach KS 1991 The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129:2000-2010
67. Seo HS, Larsimont D, Querton G, El Khissiin A, Laios I, Legros N, Leclercq G 1998 Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breastcancer cells: comparison of immunocytochemical data with biochemical measurements. Int J Cancer 78:760-765
68. Alarid ET, Bakopoulos N, Solodin N 1999 Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 13:1522-1534
69. El Khissiin A, Leclercq G 1999 Implication of proteasome in estrogen receptor degradation. FEBS Lett 448:160-166
70. Berry M, Nunez A-M, Chambon P 1989 Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 86:1218-1222
71. Warnmark A, Treuter E, Gustafsson JA, Hubbard RE, Brzozowski AM, Pike AC 2002 Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor α. J Biol Chem 277:21862-21868
72. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP 1999 Peptide antagonists of the human estrogen receptor. Science 285:744-746
73. Benecke A, Chambon P, Gronemeyer H 2000 Synergy between estrogen receptor α activation functions AF-1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Rep 1:151-157
74. Voegel JJ, Heine M, Zechel C, Chambon P, Gronemeyer H 1996 Tif2, a 160 kda transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667-3675
75. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H 1998 The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 17:507-519
76. Tamrazi A, Carlson KE, Katzenellenbogen JA 2003 Molecular sensors of estrogen receptor conformations and dynamics. Mol Endocrinol 17:2593-2602
77. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M 1999 Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J 18:4608-4618
78. Gangloff M, Ruff M, Eiler S, Duclaud S, Wurtz JM, Moras D 2001 Crystal structure of a mutant hERα ligand-binding domain reveals key structural features for the mechanism of partial agonism. J Biol Chem 276:15059-15065
79. Johnson BA, Wilson EM, Li Y, Moller DE, Smith RG, Zhou G 2000 Ligand-induced stabilization of PPARγ monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol 298:187-194
80. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL 2005 Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18:413-424
81. Marimuthu A, Feng W, Tagami T, Nguyen H, Jameson JL, Fletterick RJ, Baxter JD, West BL 2002 TR surfaces and conformations required to bind nuclear receptor corepressor. Mol Endocrinol 16:271-286
82. Long X, Nephew KP 2006 Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α. J Biol Chem 281:9607-9615
83. Green S, Issemann I, Sheer E 1988 A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 16:369
84. Nguyen D, Steinberg SV, Rouault E, Chagnon S, Gottlieb B, Pinsky L, Trifiro M, Mader S 2001 A G577R mutation in the human AR P box results in selective decreases in DNA binding and in partial androgen insensitivity syndrome. Mol Endocrinol 15:1790-1802
85. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
86. Jones TA, Zou JY, Cowan SW, Kjeldgaard 1991 Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119
87. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M 2000 Detection of β 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 97:3684-3689